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Introduction: Dupuytren’s contracture (DC) is a chronic fibroproliferative disease of the hand, which is characterized
by uncontrolled proliferation of atypical myofibroblasts at the cellular level. We hypothesized that specific areas of the
DC tissue are sustaining the cell proliferation and studied the potential molecular determinants that might contribute
to the formation of such niches.
Methods: We studied the expression pattern of cell proliferation marker Ki67, phosphorylated AKT (Ak mouse
strain thymoma) kinase, DC-associated growth factors (connective tissue growth factor (CTGF), basic fibroblast
growth factor (bFGF), insulin-like growth factor 2 (IGF-2)) and extracellular matrix components (laminins,
fibronectin, collagen IV) in DC tissue and normal palmar fascia using immunofluorescence microscopy and
quantitative real-time polymerase chain reaction (qPCR).
Results: We found that proliferative cells in the DC nodules were concentrated in the immediate vicinity of small
blood vessels and localized predominantly in the myofibroblast layer. Correspondingly, the DC-associated blood
vessels contained increased levels of phosphorylated AKT, a hallmark of activated growth factor signaling. When
studying the expression of potential activators of AKT signaling we found that the expression of bFGF was
confined to the endothelium of the small blood vessels, IGF-2 was present uniformly in the DC tissue and CTGF
was expressed in the DC-associated sweat gland acini. In addition, the blood vessels in DC nodules contained
increased amounts of laminins 511 and 521, which have been previously shown to promote the proliferation and
stem cell properties of different cell types.
Conclusions: Based on our findings, we propose that in the DC-associated small blood vessels the presence of
growth factors in combination with favorable extracellular matrix composition provide a supportive environment
for sustained proliferation of myofibroblasts and thus the blood vessels play an important role in DC pathogenesis.Introduction
Dupuytren’s contracture (DC) is a chronic, progressive
fibroproliferative disease of the hand, which affects 4 to
11 % of general population [1, 2]. It is widely accepted that
uncontrolled proliferation of atypical fibroblasts forms the
cellular basis of DC. Nodules, which are formed by prolif-
erative myofibroblasts and contain an increased number* Correspondence: viljar.jaks@ut.ee
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ease [3]. As DC progresses differentiation of fibroblasts
leads to formation of thickened collagen-rich cords, which
cause flexion deformity of the affected fingers and a severe
reduction in hand function [1, 4]. Clinically, DC is remin-
iscent of a benign dysplastic disorder. It does not dissem-
inate to other tissues but can invade locally and has a
progressive and irreversible course [5].
Despite the extensive research addressing this disease,
the exact etiology and pathogenetic mechanisms of DC
remain largely unknown. A complex network of events,
including deregulation of cytokine and growth factor
signaling along with changes in the extracellular matrixdistributed under the terms of the Creative Commons Attribution
by/4.0), which permits unrestricted use, distribution, and reproduction in
operly credited. The Creative Commons Public Domain Dedication waiver
/1.0/) applies to the data made available in this article, unless otherwise stated.
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implicated in the progression of the DC [6, 7]. Systemic
analysis of the proteome and transcriptome of the DC
cells have shown that aberrant activation of Ak mouse
strain thymoma-associated (AKT) kinase, mitogen-
activated protein kinase (MAPK) and transforming
growth factor β (TGF-β) pathways play a prominent role
in DC pathogenesis by inducing cell proliferation and fi-
brosis correspondingly [3, 8, 9]. A few growth factors,
which are thought to activate the AKT and MAPK path-
ways in DC, have been identified. It has been shown that
DC tissue contains increased amounts of basic fibro-
blast growth factor (bFGF) [10]. Furthermore, cultured
DC fibroblasts have shown to synthetize connective tis-
sue growth factor (CTGF) [9, 11] and insulin-like
growth factor 2 (IGF-2) [12], which sustained their pro-
liferation in vitro.
Laminins (LM), the main components of basal mem-
brane (BM) along with collagen IV (CoIV), belong to a
well-characterized family of trimeric glycoproteins and
consist of one α, one β and one γ subunit [13]. Laminins
interact with adhesion molecules on the cell surface and
modulate intracellular signaling pathways including those
related to multipotency and stemness [14–16]. The laminin
isoform composition in the DC has been addressed before
[7, 17]; however, these studies were limited by the availabil-
ity of antibodies specific to certain laminin subunits.
In this study, we hypothesized that specific areas of
the DC tissue are sustaining the cell proliferation and
studied the potential molecular determinants that might
contribute to the formation of such niches.
We found that the proliferating cells were concentrated
in the immediate vicinity of the DC-associated blood ves-
sels, which contained increased amount of bFGF, phos-
phorylated AKT (pAKT) protein and laminins 511 and
521. Our findings suggest the presence of a supportive
microenvironment in the immediate vicinity of small
blood vessels in the DC tissue, which sustains the persist-
ent myofibroblast proliferation and promotes the progres-
sion of this disease.
Methods
Ethics statement
The procedures for sample collection and processing
were approved by the Research Ethics Committee of the
University of Tartu (permit no 221/M-34). Written in-
formed consent was obtained from the research subjects.
DC samples
DC samples were obtained from biopsies taken from
eight DC patients with extensive, stage 2 or 4 fibrosis of
the palmar fascia during open radical palmar fasciect-
omy. The nodular tissue was separated from the DC
chords and embedded in Tissue-Tek O.C.T. Compound(Sakura Finetek, Torrance, CA, USA). The embedded
samples were subsequently shifted to −80 °C until fur-
ther use. Samples of normal palmar fascia were obtained
from four patients during the open carpal tunnel release
operations and were used as controls.
Immunostaining and imaging
Frozen tissue sections (10–14 μm thick) were fixed
with 4 % formaldehyde for 10 minutes, permeabilized
with 0.1% Triton X for 10 minutes and blocked with 4
% normal goat or donkey serum in phosphate-buffered
saline (PBS) for 1 hour. Next, the tissue sections were
incubated with primary antibodies for 1 hour, followed
by the incubation of fluorochrome-labeled secondary
antibodies for 45 minutes (1:500, Life Technologies,
Carlsbad, CA, USA).
For staining with two mouse monoclonal antibodies
the staining with the first antibody was performed as
described above. Next, the sections were blocked with
M.O.M. (Mouse-On-Mouse) Mouse Ig Blocking Reagent
(Vector Laboratories, Burlingame, CA, USA) for 1 hour,
followed by the incubation with M.O.M. Diluent (Vector
Laboratories) for 5 minutes. Sections were then incu-
bated with the second set of primary and secondary anti-
bodies diluted in M.O.M. Diluent for 1 hour.
When co-staining with anti-CD105-fluorescein isothio-
cyanate (FITC) conjugate was performed, the sections
were initially stained with the first set of primary and sec-
ondary antibodies as described, then the sections were
blocked with 4 % rabbit serum in PBS containing nonspe-
cific mouse immunoglobulins (1/100) for 1 hour. Next,
the sections were incubated with CD105-FITC conjugate
for 1 hour and subsequently with rabbit anti-FITC Alexa
Fluor 488-conjugated secondary antibody for 45 minutes
(1:500, Life Technologies) to enhance the CD105 signal.
The primary antibodies used in this study are listed in
Table S1 in Additional file 1. Cell nuclei were visualized
with DAPI (1 μg/ml, Sigma-Aldrich, St Louis, MO, USA)
and sections were mounted with Fluorescent Mounting
Medium (Dako, Glostrup, Denmark). All staining proce-
dures were performed at room temperature.
The images were captured with Olympus BX61 and
IX81 fluorescence microscopes or Olympus confocal
microscope FV1000 (Olympus, Tokyo, Japan) and proc-
essed using Hokawo v2.1 (Hamamatsu Photonics,
Hamamatsu, Japan) or Imaris (Bitplane AG, Zurich,
Switzerland) software.
Quantitative real-time PCR (qPCR)
Tissue samples were immersed in RNAlater (Thermo
Fisher Scientific, Waltham, MA, USA) and stored at 4 °C
for later analysis. The tissue was homogenized in 1 ml of
TRIzol (Gibco, Carlsbad, CA, USA) by using Precellys®24
high-throughput tissue homogenizer (Precellys, Montigny-
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with 0.2 ml of chloroform and centrifuged for 15 minutes
at 12,000 × g (4 °C). The aqueous phase was transferred to
a fresh tube, and the total RNA was extracted. One micro-
gram of total RNA was reverse transcribed with RevertAid
First Strand cDNA Synthesis Kit (Thermo Fisher Scientific)
according to manufacturer’s instructions. The complemen-
tary DNA (cDNA) from each sample was loaded in tripli-
cate onto a plate with primers (10 nM) and Maxima SYBR
Green/ROX qPCR Master Mix reagents (Thermo Fisher
Scientific). All qPCR reactions were carried out with an
ABI Prism 7900 HT Sequence Detection System (Applied
Biosystems Carlsbad, CA, USA), and the data acquired
were analyzed with ABI SDS software (version 2.1 from
Applied Biosystems). Housekeeping genes HPRT1 and
RPLP0 were used as references. The following primers





CA-3′, HPRT1 5′-GCCCTGGCGTCGTGATTAG-3′, 5′-
ATAGCCCCCCTTGAGCACACA-3′, RPLP0 5′-TGCA
GATTGGCTACCCAA-3′, 5′-TTCAGCAAGTGGGAAG
GT-3′. The PCR reactions were performed at least three
times for each sample and the average value of the reads
was calculated. The box plots were generated using a free
online tool [18].
Results
Blood vessels are proliferation epicenters in the DC
To investigate in detail the distribution of proliferative
cells in the DC tissue we stained the DC and normal pal-
mar fascia (NPF) samples with antibodies recognizing the
proliferation marker Ki67 and the myofibroblast marker
smooth muscle actin (SMA). Numerous Ki67-positive
proliferating cells were identified in the DC tissue (Fig. 1a)
whereas we could not detect any Ki-67-labeled cells in the
NPF samples (Figure S1a in Additional file 2). Notably,
the Ki67-positive proliferating cells were concentrated in
the vicinity and inside of the SMA-expressing blood ves-
sels (Fig. 1a). The identity of the SMA-positive structures
as blood vessels was verified by co-staining the DC sam-
ples with SMA and endothelial marker von Willebrand’s
factor (vWF) (Figure S1b in Additional file 2). As ex-
pected, we found that the DC nodules exhibited an in-
creased overall SMA content when compared to NPF
samples (Figure S1c, d in Additional file 2). The reason for
this was an increased blood vessel number and the preva-
lence of SMA-positive myofibroblasts in DC tissue.
To study the proliferative activity of blood vessel wall
components, we additionally co-stained the DC samples
with antibodies recognizing vWF, pericyte marker des-
min and Ki67. Interestingly, a vast majority of Ki-67-positive nuclei could be found in the strongly SMA-
positive muscular layer of the blood vessels (Fig. 1b, d).
However, only a minor part of the proliferative cells
were mapped to the vWF-expressing endothelial com-
partment (Fig. 1c) and no proliferative desmin-positive
pericytes could be identified (Fig. 1e). This was con-
firmed by quantitation of the relative number of prolifer-
ative cells in the endothelial, muscular and perivascular
areas (Fig. 1f ) by counting the proliferative nuclei in
three different blood vessel compartments: in the SMA-
expressing myofibroblast layer, the endothelial compart-
ment, which is surrounded by the SMA-positive layer
and the perivascular layer located outside of the SMA-
positive layer. The obtained data confirmed our findings
that the majority of the proliferating cells are found in
the myofibroblast layer of the blood vessel wall.
DC-associated blood vessels display an activated
phenotype and contain CD105/CD90 double-positive
endothelial cells
Since we saw an increase in the numbers of proliferating
cells near the blood vessels in the DC tissue, we asked
whether activated growth factor signaling might be present
in the DC-associated blood vessels.
To test our hypothesis we stained the tissue samples
with antibodies recognizing CD90 (Thy-1) and CD105
(endoglin), as the expression of these molecules has been
associated with the activated state of the endothelial cells
in response to growth factor signaling [19, 20]. We de-
tected a number of CD105/CD90 double-positive cell
clusters located in the DC tissue (Fig. 2a, Figure S1e in
Additional file 2). To verify the endothelial localization
of CD105 we co-stained the DC samples with antibodies
recognizing CD105 and vWF. As expected, CD105 was
located in the vWF-positive endothelial cells (Fig. 2b,
Figure S1f in Additional file 2). Double-staining of the
DC samples with CD105 and SMA or desmin did not re-
veal any CD105/SMA or CD105/desmin double-positive
cells and confirmed the endothelial localization of the
CD105 expression (Fig. 2c, d). Notably, the rare small
blood vessels found in NPF did not contain CD105-
expressing cells (Figure S1g in Additional file 2). As ex-
pected, SMA-expressing myofibroblasts surrounded the
CD90-expressing endothelial compartment and did not
show any CD90 positivity (Fig. 2e, Figure S1h in Additional
file 2). Similarly, the desmin-expressing pericyte compart-
ment, which enclosed the CD90-expressing endothelium,
was generally devoid of CD90-expressing cells and only
very rare desmin/CD90 double-positive pericytes could be
identified in the blood vessel wall (Fig. 2f). The endothe-
lium of the vessels found in NPF samples, however, only
very rarely contained CD90-expressing cells (Figure S1i in
Additional file 2). As expected, the proliferating cells were
located in the close proximity of the CD105-expressing
Fig. 1 Proliferative cells locate prevalently in the myofibroblast compartment of small blood vessels in DC. Sections were stained with antibodies
recognizing SMA, vWF, desmin and Ki67 as indicated on the panels. Proliferative Ki67-positive cells concentrate around and inside the small
blood vessels in DC (a) and are located prevalently in the SMA-positive myofibroblast compartment of the blood vessels (b, d, violet arrows).
(d) represents a surface-rendering model of an image stack obtained with a confocal microscope. Proliferative nuclei (violet arrows) are embedded
in the SMA-expressing myofibroblast layer (green). Rare Ki67-positive cells were found in the vWF-positive endothelial compartment (c, white arrows),
which is located inside the SMA-stained myofibroblast layer (b, white arrow). No proliferative cells could be detected among the desmin-labeled
pericytes (e). Quantitation of the relative number of proliferative cells inside and in the immediate vicinity of the blood vessel wall (f, 6 patients, 45
sections) reveals that the majority of the proliferative cells are found in the myofibroblast layer. Scale bars: 20 μm. DC Dupuytren’s contracture, SMA
smooth muscle actin, vWF von Willebrand’s factor
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correlation with our previous results (Fig. 2g, see also
Fig. 1a, b, d).
The blood vessels in the DC tissue contain cells with
activated AKT signaling
Since AKT pathway has been implicated in the patho-
genesis of the DC [8], we hypothesized that activated
AKT signaling might be involved in driving the enhanced
proliferation in the vascular/perivascular compartment.
To study the activation status of the AKT pathway we co-
stained the DC samples with antibodies recognizing an ac-
tivated and phosphorylated AKT (pAKT) isoform. We
could readily detect the presence of pAKT in all the layers
of SMA-positive blood vessels and their immediate vicin-
ity (Fig. 3a). Interestingly, we did detect a high level of
pAKT also in the acini and ducts of sweat glands (Fig. 3b),which were surrounded by small blood vessels. The
identity of the sweat glands was verified by the keratin
15 (K15) and basement membrane marker CoIV stain-
ing (Fig. 3c). The K15-positive acinar basal epithelium
of sweat glands is surrounded by CoIV-rich basement
membrane, in contrast the ducts are negative for K15
and show less intensive CoIV staining similar to the sur-
rounding blood vessels (Fig. 3c).
Since CTGF, bFGF and IGF-2 activate AKT kinase and
have been implicated in the pathogenesis of DC [9, 10,
12, 21] we set out to investigate their expression in the
NPF and DC samples. We found that the mRNA expres-
sion of all the three analyzed growth factors was increased
in the DC samples when compared to NPF (Fig. 3d–f ).
When probing the DC tissue sections with anti-CTGF
antibody a strong signal was detected in the K15-positive
acini of the sweat glands (Fig. 3g). CTGF expression was
Fig. 2 CD105 and CD90 label endothelial cells in the DC tissue. DC samples were stained with antibodies recognizing CD90, CD105, vWF, SMA
and desmin as indicated on the panels. CD105/CD90 double-positive cells localized in blood vessels in the DC tissue (a). CD105 is localized
in vWF-expressing endothelial cells (b). No CD105-expressing cells can be identified in the SMA-positive myofibroblast layer encompassing CD105-
positive endothelial cells (c). Desmin-positive pericytes surround vWF-expressing endothelial cells and no CD105/desmin double-positive cells can be
identified (d). No CD90/SMA double-positive myofibroblasts could be identified (e). Desmin-positive pericytes surround CD90-expressing cells with a
few desmin/CD90 double-positive cells (f, arrows). Ki67-expressing proliferative cells are concentrated in the vicinity of CD105-expressing activated
endothelium (g). Scale bars: 20 μm. DC Dupuytren’s contracture, SMA smooth muscle actin, vWF von Willebrand’s factor
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negative sweat gland ducts and blood vessels (Fig. 3h).
This suggests a hitherto unknown role for sweat glands in
the pathogenesis of DC. Despite the activated pAKT sig-
naling present both in the acini and ducts, the proliferative
cells were located mainly in the sweat gland ducts while
the CTGF-secreting cells in the acini did not show Ki67
positivity (Fig. 3i). The expression of IGF-2 was uniformly
distributed over the DC tissue without any preference in
respect of small blood vessels (Fig. 3j–l). Interestingly, the
expression of bFGF was confined to the endothelium of
the small blood vessels (Fig. 3m, n) correlating well with
the increased number of proliferative cells in and near the
blood vessels.
Laminins 411/421, 511/521 and fibronectin are associated
with the enhanced proliferation in the DC-associated
blood vessels
Next, we asked whether specific components of the ECM
might be present in the areas of DC tissue with increasedproliferation. To describe in detail the constitution of the
ECM in DC tissue, we stained tissue samples with anti-
bodies recognizing human laminin subunits α2-α5, β1-β3,
γ1-γ3, CoIV and fibronectin (FN).
The expression of laminin subunits α4, α5, β1, β2,
and γ1 was detected in the DC tissue (Figure S2a-e in
Additional file 3) but not in the NPF samples (Figure
S2f-j in Additional file 3). However, we were not able to
detect the expression of laminin subunits α2, α3, β2,
β3, γ2 and γ3 neither in DC tissue (Figure S3a-d in
Additional file 4) nor in NPF samples (Figure S3e-h in
Additional file 4). The obtained data suggest that laminins
411, 421, 511 and 521 are contained in DC nodules. Since
these laminin isoforms are expressed in vascular basement
membranes [22] we co-stained the samples with anti-
bodies specific for vWF or SMA and laminin subunits α4,
α5, β1, β2, and γ1 (Fig. 4). The studied laminin subunits
co-localized with the SMA-expressing myoepithelial cells
(β1, β2: Fig. 4b, c) and surrounded the vWF positive
endothelium (α4, α5, γ1: Fig. 4d, e, f ) showing their
Fig. 3 AKT pathway activation and the expression of CTGF, IGF-2 and bFGF in the DC tissue. DC samples were stained with antibodies recognizing
SMA, phosphorylated AKT at T308 (pAKT), collagen IV (CoIV), keratin15 (K15), CTGF, IGF-2, bFGF and Ki67 as indicated on the panels. Nuclei were
counterstained with DAPI. pAKT was detected in blood vessels (a,b; blue arrows), sweat gland acini (b; violet arrows) and sweat gland ducts
(b; white arrows). Sweat gland acini were identified as containing characteristic K15-positive basal epithelium, which is encompassed by
CoIV-positive basement membrane (BM; c; violet arrows). Sweat gland ducts (c; white arrows) and blood vessels (c; blue arrows) are negative
for K15 and contain weakly CoIV-positive BM. The expression of CTGF (d), IGF-2 (e) and bFGF (f) was detected using qPCR in DC (n = 8) and NPF
(n = 4) samples. Center lines show the medians; box limits indicate the 25th and 75th percentiles; whiskers extend 1.5 times the interquartile
range from the 25th and 75th percentiles. The expression of all three growth factors was increased in DC samples when compared to NPF.
K15-positive sweat gland acini synthetize CTGF (g, h; violet arrows) whereas ducts (h; white arrows) and blood vessels (g, h; blue arrows) are
negative for CTGF. Sweat gland ducts contain dividing Ki67-positive cells (i; white arrows) while CTGF-expressing SMA-positive acini are not
proliferative (i; violet arrow). IGF-2 is expressed throughout the DC tissue (j-l). The color-split images of (j) for IGF-2/DAPI (k) and SMA/vWF (l) are
presented to underline the uniform distribution of IGF-2 expression in the DC tissue. bFGF co-localizes with vWF and thus is expressed in the
endothelium of the DC-associated blood vessels as presented by cross (m) and longitudinal sections (n) of blood vessels. Scale bars: 50 μm. AKT
Ak mouse strain thymoma-associated, bFGF basic fibroblast growth factor, CTGF connective tissue growth factor, DC Dupuytren’s contracture,
IGF-2 insulin-like growth factor 2, NPF normal palmar fascia, qPCR quantitative polymerase chain reaction, SMA smooth muscle actin
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blood vessel wall. The laminin subunits α4, α5, β1, β2
and γ1 co-localized also with CoIV (Figure S3i-m in
Additional file 4), which suggests that assembled basementmembrane is present in the myoepithelial compartment of
the blood vessel wall. Thus, the lack of laminins in NPF
samples could be explained with the scarcity of blood
vessels in NPF.
Fig. 4 Laminins 411/421 and 511/521 localize in the small blood vessels in DC. The DC samples were stained with antibodies recognizing laminin
subunits α4, α5, β1, β2 and γ1; vWF and SMA as indicated on the panels. SMA-labeled myofibroblast layer surrounds the vWF-positive endothelium in
the blood vessels found in the DC tissue (a). Laminin subunits β1, β2, α4, α5 and γ1 (b, c, d, e and f) localize in the SMA- (b, c) or vWF-labeled (d, e, f)
small blood vessels. Scale bars: 100 μm. DC Dupuytren’s contracture, SMA smooth muscle actin, vWF von Willebrand’s factor
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and NPF samples. In agreement with previous reports
[23], the FN amount in DC was increased when compared
to NPF samples (Figure S3n, o in Additional file 4) and the
signal was more intensive in the laminin-positive blood
vessels (compare Figure S3o, p in Additional file 4).
Discussion
Despite the widespread nature of Dupuytren’s contrac-
ture, knowledge regarding the cellular and molecular
mechanisms underlying the disease is still fragmentary.
It is a widely accepted view that uncontrolled prolifera-
tion and accumulation of contractile myofibroblasts
underlies the pathogenesis of DC [3]. In this work we
sought to shed light on the molecular and structural de-
terminants that sustain this process.
When studying the distribution of the proliferative
cells in the DC tissue we found that these were concen-
trated in the small blood vessels or in their immediate
vicinity. It has been shown previously that small blood
vessels can act as stem cell niches in normal and malig-
nant brain tissue [24, 25]. Our results suggest a compar-
able role for small blood vessels in DC, which might
provide a favorable microenvironment for sustaining myo-
fibroblast proliferation.
When looking for the cells positive for mesenchymal
stem cell markers we found that endothelial cells in the
blood vessels of DC nodules were double-positive for
CD90 and CD105. CD90 is expressed on the activated
endothelial cells in an inflammatory tissue and is neces-
sary for the attachment of leukocytes to the endothelium
([26] and references therein). CD105 is found in the
endothelium of immature blood vessels of developing
tissues and in blood vessels associated with malignanttumors [27–29]. Thus, the expression of CD90 and CD105
in the blood vessels of the DC tissue correlates well with
the presence of an inflammatory process associated with
enhanced cell proliferation. Indeed, proteomic studies have
put forward the proproliferative AKT signaling pathway,
which is activated in response to growth factor stimulation,
as a prominent player in DC pathogenesis [8]. In agree-
ment with this notion, we detected elevated levels of phos-
phorylated AKT, a hallmark of activated AKT signaling, in
the blood vessels and sweat glands within the DC nodule.
Interestingly, the endothelial cells and the desmin-positive
pericytes showed little response to the presence of prolifer-
ative signals. In contrast the SMA-expressing myofibro-
blasts present in the perivascular compartment and in the
blood vessel wall contained a number of proliferative cells
positive for the proliferation marker Ki67, showing that
myofibroblasts are the most responsive cells to the pro-
proliferative signaling present in the DC tissue. How-
ever, whether the proliferative myofibroblasts present in
the blood vessel wall contribute substantially to the bulk
of the DC nodule needs further studies.
A few proproliferative growth factors have been impli-
cated in the pathogenesis of DC. Blood vessels in DC
nodules express high levels of basic fibroblast growth
factor (bFGF) [10] and it has been proposed that persist-
ent TGF-β signaling in conjunction with increased bFGF
levels might be responsible for the increased prolifera-
tion and fibrosis taking place in DC [30]. IGF-2 has been
shown to regulate cellular contractility and proliferation
in DC [12] and recently it was suggested that CTGF, a
TGF-β target gene and a potent activator of the AKT
signaling pathway is implicated in the pathogenesis of
fibrotic diseases including DC [11, 21]. CTGF is secreted
by cultivated endothelial cells [31] and therefore we
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lium might synthesize this growth factor. Surprisingly,
no CTGF signal was detected in the endothelial cells,
however, the acinar cells of DC-associated sweat glands
were positive for this molecule, which suggest that sweat
glands might have an hitherto unrecognized role in the
development of DC lesions by providing proproliferative
profibrotic CTGF signaling to the DC tissue (Fig. 5a, b).
Furthermore, the inhibition of CTGF might be a promis-
ing novel therapeutic approach in the DC treatment
since corresponding inhibitors are available and areFig. 5 A schematic overview of growth factor signaling in DC. DC
tissue was stained with antibodies recognizing SMA and vWF. Sweat
glands (SG), which contain SMA-positive acini (a; violet arrows),
SMA-negative ducts (a; white arrows) and SMA/vWF double-positive
blood vessels are located adjacent to the SMA-rich DC nodule, which
contains vWF-expressing blood vessels (a). Scale bar: 200 μm. bFGF
synthetized by the endothelial cells and IGF-2 present throughout
the DC tissue synergize in the ECM-rich myofibroblast layer of the
blood vessels to form a supportive environment for sustained cell
proliferation in the vascular and perivascular compartments. Sweat
glands synthesize profibrotic CTGF, which, in combination with growth
factors present in the DC tissue, facilitates the development of fibrosis
(b). bFGF basic fibroblast growth factor, CTGF connective tissue growth
factor, DC Dupuytren’s contracture, EMC extracellular matrix, IGF-2
insulin-like growth factor 2, SMA smooth muscle actin, vWF von
Willebrand’s factorcurrently undergoing clinical trials as treatments for
hematopoietic malignancies [21].
The composition of the ECM plays a critical role in
the regulation of cell fate and regenerative potential
[32]. We found that laminin subunits α4, α5, β1, β2, and
γ1, which correspond to laminins 411/421 and 511/521,
were enriched in the DC tissue. These laminins are
normal components of the endothelial basement mem-
brane [22] and as expected we found that the high
laminin content of the DC nodule is caused by the in-
creased vascularization.
Conclusions
The somatic stem cells are often confined to stem cell
niches - areas with specific microenvironment, which
maintains their unique properties. It can be envisaged
that the presence of supportive ECM molecules in con-
junction with the presence of oxygen supply and nutri-
ents create a favorable microenvironment in the vicinity
of small blood vessels, which sustains the cell renewal in
the DC nodule. Notably, laminins 511 and 521 have been
shown to support the undifferentiated state of mouse and
human embryonic stem cells (hESC) and keratinocytes
[15, 16]. Furthermore, the cooperative action of IGF-2 and
bFGF plays a crucial role in the establishment of the regu-
lative niche for hESC [33], which sustains the pluripotent
properties of hESC. This suggests that the combined ac-
tion of bFGF and IGF-2 in the context of high laminin
511/521 content in the surrounding ECM might provide a
supportive environment for the persistence of cells with
enhanced proliferative potential also in the DC nodules.
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